Oral Solid Dose Formulation Development Service
Overview
In the contemporary biopharmaceutical landscape, the oral route remains the preferred modality for drug administration due to high patient compliance, ease of self-administration, and manufacturing cost-efficiencies. However, as molecular complexity increases, developers frequently encounter significant hurdles related to poor aqueous solubility, limited membrane permeability, and metabolic instability. CD BioGlyco provides high-end oral solid dose (OSD) formulation development services designed to navigate these challenges through rigorous scientific methodology and innovative engineering.
Leveraging deep expertise in physicochemical characterization and pharmacokinetic optimization, CD BioGlyco transforms challenging active pharmaceutical ingredients (APIs) into robust, stable, and bioavailable solid dosage forms. Our approach integrates "quality by design" (QbD) and "failure mode and effects analysis" (FMEA) to ensure that every formulation is not only effective in the clinic but also fully optimized for large-scale commercial manufacturing. We focus on bridging the gap between discovery-phase molecules and market-ready products, ensuring the highest possible quality.
Core Technologies
We utilize a suite of cutting-edge technologies to enhance drug performance and ensure manufacturing robustness:
- Amorphous Solid Dispersions (ASD)
Utilizing spray drying and hot-melt extrusion to stabilize poorly soluble APIs in a high-energy amorphous state, significantly enhancing dissolution rates and bioavailability for BCS Class II and IV compounds.
- Precision Granulation & Particle Engineering
Advanced high-shear and fluid-bed granulation techniques to optimize flowability, compressibility, and content uniformity, ensuring consistent performance in high-speed tableting operations.
- Multi-Particulate Systems (Pellets/Beads)
Engineering functionalized beads through extrusion-spheronization or layering, allowing for complex release profiles and the combination of incompatible APIs within a single dosage unit.
- Controlled and Targeted Release Coatings
Expert application of pH-dependent, time-dependent, and moisture-barrier coatings to protect sensitive molecules and ensure drug release at the optimal site within the gastrointestinal tract.
From Research Concept to Robust Production.
CD BioGlyco offers an expansive range of development services tailored to the specific needs of modern drug pipelines. Our scope encompasses the development of traditional tablets and capsules, as well as complex, high-value delivery formats. We specialize in fixed-dose combinations (FDC), which allow for the co-formulation of two or more APIs into a single dosing unit, optimizing treatment regimens for chronic conditions like hypertension and diabetes.
Our capabilities include the design of:
- Immediate-release (IR) formulations: Engineered for rapid disintegration and absorption.
- Modified-release (MR) formulations: Including extended, sustained, and delayed-release architectures to maintain therapeutic windows and reduce dosing frequency.
- Orally disintegrating tablets (ODT): Patient-centric designs for pediatric and geriatric populations who face swallowing difficulties.
- Pediatric mini-tablets: Precisely dosed, small-format OSDs to ensure safety and compliance in younger patients.
We also provide specialized support for moisture-sensitive and oxygen-sensitive APIs through advanced primary packaging selection and stabilization strategies. By integrating early-stage biopharmaceutical modeling with downstream manufacturing expertise, we ensure that the final OSD product is optimized for both biological performance and commercial viability.
Workflow
Comprehensive Pre-formulation
We initiate the process with exhaustive physicochemical characterization of the active ingredient. This includes precise determination of pKa, logP, and pH-dependent solubility profiles, alongside thorough crystal form screening and polymorphism assessment. This data-driven foundation is critical for rational formulation design, enabling the selection of optimal salts, forms, and delivery strategies to maximize stability and bioavailability from the outset.
Excipient Compatibility & Prototype Design
Leveraging our extensive library of GRAS-certified and novel functional excipients, we design and screen multiple prototype formulations. These iterations are rigorously evaluated through accelerated stability studies and in vitro biorelevant dissolution assays that simulate the gastrointestinal environment. This systematic approach identifies the most compatible and robust formulation candidate early in the development cycle.
Process Development & Optimization
We employ QbD principles, utilizing structured design of experiments (DoE) protocols to define and optimize critical process parameters (CPPs) for key unit operations such as blending, granulation (wet/dry), and compression. This methodology ensures a fully understood and controllable "design space," guaranteeing that the manufacturing process is robust, reproducible, and capable of consistently producing tablets that meet all critical quality attributes (CQAs).
Analytical Method Development
In parallel with formulation activities, we develop, validate, and transfer specific analytical methods. This includes stability-indicating HPLC/UPLC assays for potency and purity, discriminating dissolution methods, and techniques for impurity profiling and identification. These methods are designed to meet stringent regulatory requirements, providing comprehensive control over the drug product's quality, stability, and performance throughout its lifecycle.
Scale-Up & Tech Transfer
The optimized formulation and process are seamlessly transitioned from lab-scale to pilot and commercial-scale manufacturing. We provide comprehensive scale-up support, including drafting of master batch records and process validation protocols. This end-to-end support de-risks the scale-up journey and accelerates the path to clinical supply and commercial launch.
Publication Data
Journal: Progress in Additive Manufacturing.
DOI: 10.1007/s40964-020-00127-5
IF: 5.4
Published: 2020
Results: In this comprehensive review, Curti et al. systematically examine the current application of three-dimensional (3D) printing technologies in the design and development of solid oral dosage forms, highlighting their potential to revolutionize personalized medicine. The authors detail various additive manufacturing techniques, including powder-bed inkjet printing, pressure-assisted microsyringe printing, fused deposition modeling, selective laser sintering, and stereolithography, discussing their respective advantages in enabling precise control over dosage, release profiles, geometry, and size of tablets through digital design. They emphasize how these methods facilitate the creation of complex drug delivery systems, such as multi-layer polypills and fast-disintegrating tablets, while addressing formulation challenges like material compatibility and thermal stability. The review also explores practical applications in on-demand production and tailored therapies, alongside regulatory hurdles and future directions, positioning 3D printing as a transformative tool for advancing pharmaceutical manufacturing and patient-specific treatments.
Applications
Oncology Therapeutics
Developing high-potency oral solid doses for targeted cancer therapies, ensuring safe handling and precise dosing of cytotoxic agents while maximizing oral bioavailability for better patient outcomes.
Neurological Disorders
Engineering controlled-release OSDs for CNS drugs to maintain steady plasma concentrations, reducing side effects and improving therapeutic efficacy for conditions like Parkinson's disease and epilepsy.
Cardiovascular Medicine
Creating stable and reliable formulations for anti-hypertensives and anti-coagulants, often utilizing fixed-dose combinations to simplify complex medication regimens and improve long-term patient adherence.
Rare & Orphan Diseases
Tailoring small-batch, high-value OSD formulations for niche patient populations, ensuring that even the most complex and specialized molecules receive the highest level of developmental rigor.
Advantages
QbD Integration
We embed QbD principles into every project phase. By defining the relationship between material attributes and final product quality early on, we ensure a robust manufacturing process that minimizes batch failures and regulatory hurdles.
Accelerated Development Timelines
Our streamlined workflow and high-throughput screening capabilities significantly reduce the time from pre-formulation to clinical batch production. We help you hit critical milestones faster, providing a significant competitive advantage in the market.
Superior Content Uniformity
For low-dose and high-potency compounds, we employ specialized micronization and blending techniques. Our processes consistently achieve RSD values below 2%, ensuring safety and therapeutic consistency.
Advanced Stability Enhancement
We specialize in stabilizing oxygen- and moisture-sensitive APIs. Through the use of specialized antioxidants, desiccants, and barrier coatings, we extend product shelf-life and maintain molecular integrity under varying environmental conditions.
Frequently Asked Questions
Customer Review
CD BioGlyco delivered an exceptional ASD formulation for our lead CNS candidate. Their technical depth in managing polymorphic stability saved us months of rework.
— By Dr. A. Miller, Senior Director of Formulation
CD BioGlyco's expertise in high-potency OSDs is unmatched. They handled our cytotoxic molecule with the utmost safety and precision, delivering a mini-tablet formulation that was perfect for our pediatric trial.
— By Head of CMC, Rare Disease Biotech
The stability-indicating methods developed by CD BioGlyco were incredibly rigorous. They identified a degradation pathway we had missed, allowing us to stabilize our moisture-sensitive API before entering clinical trials.
— By Principal Scientist, Cardiovascular Unit
Associated Services
To provide a holistic therapeutic solution, we offer complementary delivery platforms for advanced molecular types.
Peptide-Therapeutic Oligonucleotide Delivery Service
Specialized oral and systemic delivery strategies for synthetic peptides and oligonucleotides.
LNP-Therapeutic Oligonucleotide Delivery Service
Advanced lipid nanoparticle systems for the protection and targeted delivery of nucleic acid payloads.
PEG-Therapeutic Oligonucleotide Delivery Service
Utilizing PEGylation to enhance the half-life and stability of complex therapeutic molecules.
CD BioGlyco is a premier partner for OSD formulation development, offering a rare blend of scientific innovation and manufacturing pragmatism. From overcoming extreme solubility challenges to engineering complex controlled-release systems, our team ensures that your OSD candidates are developed with precision, stability, and scalability as core priorities. Contact us!
Reference
- Curti, C.; et al. Current formulation approaches in design and development of solid oral dosage forms through three-dimensional printing. Progress in Additive Manufacturing. 2020, 5(2): 111-123. (Open Access)